Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.01 USD
Change Today 0.00 / 0.00%
Volume 0.0
DGEN On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/20/15 All times are local (Market data is delayed by at least 15 minutes).

deltagen inc (DGEN) Snapshot

Open
$0.01
Previous Close
$0.01
Day High
$0.01
Day Low
$0.01
52 Week High
08/11/14 - $0.09
52 Week Low
05/29/14 - $0.0026
Market Cap
392.4K
Average Volume 10 Days
1.2K
EPS TTM
$-1.54
Shares Outstanding
38.9M
EX-Date
05/17/07
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DELTAGEN INC (DGEN)

Related News

No related news articles were found.

deltagen inc (DGEN) Related Businessweek News

No Related Businessweek News Found

deltagen inc (DGEN) Details

Deltagen, Inc. provides drug discovery tools and services to the biopharmaceutical industry and to the academic research community in the United States. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was founded in 1997 and is headquartered in San Mateo, California.

deltagen inc (DGEN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

deltagen inc (DGEN) Key Developments

Deltagen Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Deltagen Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenues totaled $0.870 million. The revenues were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company's DeltaOneTM program. Net income before provision for income taxes for the year ended December 31, 2014 was $0.156 million.

Deltagen, Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2013

Deltagen Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2013. The company's consolidated revenues for the three months ended March 31, 2013 totaled $0.194 million. The revenues in the first quarter of 2013 were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company's DeltaOne(TM) program. The consolidated revenues for the period included $0.040 million for Xenopharm Inc. Consolidated net losses before provision for income taxes for the three months ended March 31, 2013 were $0.541 million, which included a net loss of $0.063 million from operations and a recognized net loss of $0.478 million from investments made by the Company in Benten BioServices Inc., which was accounted for using the Equity Method of Accounting. Income from operations was $63,000. loss before provision for income taxes and net loss was $604,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGEN:US $0.01 USD 0.00

DGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DGEN.
View Industry Companies
 

Industry Analysis

DGEN

Industry Average

Valuation DGEN Industry Range
Price/Earnings 2.1x Not meaningful
Price/Sales 0.4x
Price/Book 0.2x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELTAGEN INC, please visit www.deltagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.